Erratum to Barco et al. "Home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban. Rationale and design of the Hot-PE Trial" (Thromb Haemost 2016; 116: 191-197)

In the original article by Barco et al. "Home Treatment of Patients with Low-Risk Pulmonary Embolism with the Oral Factor Xa Inhibitor Rivaroxaban. Rationale and Design of the Hot-PE Trial" two members of the HoT-PE Trial Steering Committee and co-authors of the paper, Professors Christine Espinola-Klein and Philipp Wild, were omitted by mistake. Unfortunately, due to a technical failure, these colleagues did not receive the manuscript when it was circulated within the steering committee, and thus did not appear in the initial author list. All authors confirm that both colleagues were, and continue to be, actively involved, together with the other authors of the manuscript, in the design of the HoT-PE trial and the writing of the study protocol, the preparation of the submission of the trial to the ethics committees (EC) and competent authorities (CA), and the correspondence/response to queries of EC and CA until final approval was obtained, the coordination of the study sites and teams throughout the performance of the trial (ongoing task).

The corrected list of authors and affiliations is as follows:

Stefano Barco1; Mareike Lankeit1; Harald Binder2; Sebastian Schellong3; Michael Christ4; Jan Beyer-Westendorf5; Daniel Duerschmied6; Rupert Bausachs7; Klaus Empen8; Matthias Held9; Martin Schweiblmair10; Cândida Fonseca11; David Jiménez12; Cecilia Becattini13; Kurt Quitzau1; Christine Espinola-Klein14; Philipp Wild1,15,16; Stavros Konstantinides1,17

1Center for Thrombosis and Hemostasis (CTH), University Medical Center of the Johannes Gutenberg University, Mainz, Germany; 2Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI) at the University Medical Center Mainz, Germany; 3Municipal Hospital of Dresden-Friedrichstadt, Dresden, Germany; 4Department of Emergency and Critical Care Medicine, Paracelsus Medical University, General Hospital, Nuernberg, Germany; 5Center for Vascular Medicine and Department of Medicine III, Division of Angiology, University Hospital, Carl Gustav Carus, Dresden, Germany; 6Heart Center, University of Freiburg, Freiburg, Germany; 7Department of Vascular Medicine, Klinikum Darmstadt GmbH, Darmstadt, Germany; 8Department of Internal Medicine, Ernst Moritz Arndt University, Greifswald, Germany; 9Medical Mission Hospital, Department of Internal Medicine, Academic Teaching Hospital of the Juliius-Maximilian University of Wuerzburg, Wuerzburg, Germany; 10Klinikum Augsburg, I. Medizinische Klinik, Augsburg, Germany; 11Hospital S. Francisco Xavier/CHLO, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisbon, Portugal; 12Respiratory Department, Ramón y Cajal Hospital, IRYCIS, Madrid, Spain; 13Internal and Cardiovascular Medicine – Stroke Unit, University of Perugia, Italy; 14Center for Cardiology, Cardiology I, University Medical Center of the Johannes Gutenberg University, Mainz, Germany; 15Preventive Cardiology and Preventive Medicine, Center for Cardiology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany; 16German Center for Cardiovascular Research (DZHK), Partner Site RheinMain, Mainz, Germany; 17Department of Cardiology, Democritus University of Thrace, Alexandroupolis, Greece.

http://dx.doi.org/10.1160/TH16100001
Thromb Haemost 2016; 116: 775